Filippo Spriano

10PUBLICATIONS
74CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 11, 2025
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma.

Laurence K Jennings, Filippo Spriano, Maggie M Reddy

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Jun 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas.

Chiara Tarantelli, Filippo Spriano, Elisa Civanelli

|Apr 01, 2025
Development of C646-Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300.

Francesco Fiorentino, Filippo Spriano, Daniela Tomaselli

|Feb 07, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.

Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

Pageof 2